FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Fosinopril Sodium And Hydrochlorothiazide, and what generic alternatives are available?
Fosinopril Sodium And Hydrochlorothiazide is a drug marketed by Ani Pharms, Aurobindo Pharma, Chartwell Rx, Invagen Pharms, Mylan, Sandoz, Sun Pharm Inds Ltd, and Teva. and is included in nine NDAs.
The generic ingredient in FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE is fosinopril sodium; hydrochlorothiazide. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the fosinopril sodium; hydrochlorothiazide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fosinopril Sodium And Hydrochlorothiazide
A generic version of FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE was approved as fosinopril sodium; hydrochlorothiazide by SANDOZ on September 28th, 2005.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE?
- What are the global sales for FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE?
- What is Average Wholesale Price for FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE?
Summary for FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE
| US Patents: | 0 |
| Applicants: | 8 |
| NDAs: | 9 |
